These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 11104617

  • 21. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L, Tempfer C, Häusler G, Heinzl H, Kainz C.
    Wien Klin Wochenschr; 1998 Oct 02; 110(18):635-41. PubMed ID: 9816636
    [Abstract] [Full Text] [Related]

  • 22. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD, Choi HS, Kim SM.
    Gynecol Oncol; 2010 Jan 02; 116(1):57-60. PubMed ID: 19818996
    [Abstract] [Full Text] [Related]

  • 23. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.
    Gynecol Oncol; 2007 Jan 02; 104(1):176-80. PubMed ID: 16996584
    [Abstract] [Full Text] [Related]

  • 24. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
    Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL.
    Acta Obstet Gynecol Scand; 2006 Jan 02; 85(4):493-8. PubMed ID: 16612714
    [Abstract] [Full Text] [Related]

  • 25. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
    Xi XW, Wan XP, Li SD, Sun TW, Zhu YP.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb 02; 41(2):91-4. PubMed ID: 16640855
    [Abstract] [Full Text] [Related]

  • 26. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A.
    Cancer; 2002 Nov 01; 95(9):1886-93. PubMed ID: 12404282
    [Abstract] [Full Text] [Related]

  • 27. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R.
    Gynecol Oncol; 1995 Jul 01; 58(1):42-7. PubMed ID: 7789889
    [Abstract] [Full Text] [Related]

  • 28. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
    Margel D, Tal R, Baniel J.
    J Urol; 2007 Dec 01; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
    [Abstract] [Full Text] [Related]

  • 29. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    Gynecol Oncol; 2007 Jul 01; 106(1):69-74. PubMed ID: 17397910
    [Abstract] [Full Text] [Related]

  • 30. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA.
    Gynecol Oncol; 2010 Nov 01; 119(2):265-9. PubMed ID: 20797777
    [Abstract] [Full Text] [Related]

  • 31. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
    Kolwijck E, Span PN, Thomas CM, Bulten J, Sweep FC, Massuger LF.
    Oncol Rep; 2010 Feb 01; 23(2):579-84. PubMed ID: 20043124
    [Abstract] [Full Text] [Related]

  • 32. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC, Di Vagno G, Cormio G, Cazzolla A, Stefanelli S, D'Elia E, Selvaggi L.
    Arch Gynecol Obstet; 2004 May 01; 269(4):263-5. PubMed ID: 14745561
    [Abstract] [Full Text] [Related]

  • 33. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Riedinger JM, Eche N, Basuyau JP, Dalifard I, Hacene K, Pichon MF.
    Gynecol Oncol; 2008 May 01; 109(2):194-8. PubMed ID: 18329083
    [Abstract] [Full Text] [Related]

  • 34. [Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
    Riedinger JM, Barillot I, Coudert B, Fargeot P, Berriolo-Riedinger A, Guerrin J.
    Bull Cancer; 1996 Aug 01; 83(8):654-63. PubMed ID: 8869046
    [Abstract] [Full Text] [Related]

  • 35. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
    Deng X, Høgdall EV, Høgdall CK, Nørgaard-Pedersen B, Jørgensen M, Nielsen H, Engelholm SA.
    Gynecol Oncol; 2000 Dec 01; 79(3):416-9. PubMed ID: 11104612
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
    Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP.
    Cancer Res; 2003 Feb 15; 63(4):807-11. PubMed ID: 12591730
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant.
    Frasci G, Conforti S, Zullo F, Mastrantonio P, Comella G, Comella P, Persico G, Iaffaioli RV.
    Cancer; 1996 Mar 15; 77(6):1122-30. PubMed ID: 8635133
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.